Pressure cycling technology:a novel approach to virus inactivation in plasma

BACKGROUND: Hydrostatic‐pressure virus inactivation is a novel approach to the inactivation of pathogens in plasma and blood‐derived components, that retains the therapeutic properties of these products. STUDY DESIGN AND METHODS: A custom‐built apparatus was used to pressurize human plasma samples s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transfusion (Philadelphia, Pa.) Pa.), 2000-02, Vol.40 (2), p.193-200
Hauptverfasser: Bradley, D.W., Hess, R.A., Tao, F., Sciaba-Lentz, L., Remaley, A.T., Laugharn Jr, J.A., Manak, M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 200
container_issue 2
container_start_page 193
container_title Transfusion (Philadelphia, Pa.)
container_volume 40
creator Bradley, D.W.
Hess, R.A.
Tao, F.
Sciaba-Lentz, L.
Remaley, A.T.
Laugharn Jr, J.A.
Manak, M.
description BACKGROUND: Hydrostatic‐pressure virus inactivation is a novel approach to the inactivation of pathogens in plasma and blood‐derived components, that retains the therapeutic properties of these products. STUDY DESIGN AND METHODS: A custom‐built apparatus was used to pressurize human plasma samples spiked with lambda phage. Phage titer and plasma protein activities were monitored after pressure treatment. RESULTS: Pressure‐mediated inactivation of lambda phage was found to be an effective means for virus inactivation, particularly when performed at near‐zero (0°C) temperatures, rather than at temperatures above 20°C and below –40°C. The efficiency of inactivation was improved by an increase in applied pressure and repeated cycling from atmospheric to high pressure. In contrast, activities of plasma proteins alkaline phosphatase and total amylase did not vary with temperature and remained within 29 percent and 6 percent, respectively, of starting values after the same pressure treatments. By combining cycling, near‐zero temperatures, and high pressure, phage titers in serum were reduced approximately 6 log after 10 to 20 minutes of treatment. Activities of plasma proteins IgG, IgM, and factor X were at 104 percent, 89 percent, and 80 percent, respectively, of starting values after 20 minutes of the same temperature and pressure treatment. CONCLUSION: High‐pressure procedures may be useful for the inactivation of viruses in blood and other protein‐containing components.
doi_str_mv 10.1046/j.1537-2995.2000.40020193.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70921848</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70921848</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5113-8677844b2dd9f6fe1026618f887bc2a606e7d621a69a68997cdb0e6ba0a87eb03</originalsourceid><addsrcrecordid>eNqVkE1v1DAQhi0EokvhL6BIIG4JYyfxB5xQSwti-VQRR2viOK0Xb7LYybL77_Eq28KVkzXyM--8egh5RqGgUPGXq4LWpciZUnXBAKCoABhQVRa7e2Rx93efLAAqmlNashPyKMZVYpkC-pCcUOCSA5QLsvwSbIxTsJnZG-_662y05qYf_HC9f4VZP2ytz3CzCQOam2wcsq0LU8xcj2Z0Wxzd0Kch23iMa3xMHnToo31yfE_J94u3V2fv8uXny_dnb5a5qVObXHIhZFU1rG1VxztLgXFOZSelaAxDDtyKljOKXCGXSgnTNmB5g4BS2AbKU_Jizk21fk02jnrtorHeY2-HKWoBilFZyQS-nkEThhiD7fQmuDWGvaagDzL1Sh-E6YMwfZCpb2XqXdp-ejwzNWvb_rM720vA8yOA0aDvAvbGxb9cSWXNaMLOZ-y383b_PxX01beL2ynF5HOMi6Pd3cVg-Km5KEWtf3y61PWHcvn1Ywo5L_8AEOOgMg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70921848</pqid></control><display><type>article</type><title>Pressure cycling technology:a novel approach to virus inactivation in plasma</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Bradley, D.W. ; Hess, R.A. ; Tao, F. ; Sciaba-Lentz, L. ; Remaley, A.T. ; Laugharn Jr, J.A. ; Manak, M.</creator><creatorcontrib>Bradley, D.W. ; Hess, R.A. ; Tao, F. ; Sciaba-Lentz, L. ; Remaley, A.T. ; Laugharn Jr, J.A. ; Manak, M.</creatorcontrib><description>BACKGROUND: Hydrostatic‐pressure virus inactivation is a novel approach to the inactivation of pathogens in plasma and blood‐derived components, that retains the therapeutic properties of these products. STUDY DESIGN AND METHODS: A custom‐built apparatus was used to pressurize human plasma samples spiked with lambda phage. Phage titer and plasma protein activities were monitored after pressure treatment. RESULTS: Pressure‐mediated inactivation of lambda phage was found to be an effective means for virus inactivation, particularly when performed at near‐zero (0°C) temperatures, rather than at temperatures above 20°C and below –40°C. The efficiency of inactivation was improved by an increase in applied pressure and repeated cycling from atmospheric to high pressure. In contrast, activities of plasma proteins alkaline phosphatase and total amylase did not vary with temperature and remained within 29 percent and 6 percent, respectively, of starting values after the same pressure treatments. By combining cycling, near‐zero temperatures, and high pressure, phage titers in serum were reduced approximately 6 log after 10 to 20 minutes of treatment. Activities of plasma proteins IgG, IgM, and factor X were at 104 percent, 89 percent, and 80 percent, respectively, of starting values after 20 minutes of the same temperature and pressure treatment. CONCLUSION: High‐pressure procedures may be useful for the inactivation of viruses in blood and other protein‐containing components.</description><identifier>ISSN: 0041-1132</identifier><identifier>EISSN: 1537-2995</identifier><identifier>DOI: 10.1046/j.1537-2995.2000.40020193.x</identifier><identifier>PMID: 10686003</identifier><identifier>CODEN: TRANAT</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Inc</publisher><subject>ALP = alkaline phosphatase ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antibodies, Viral - blood ; Antibodies, Viral - physiology ; Bacteriophage lambda - physiology ; Biological and medical sciences ; Blood - virology ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; CMV = cytomegalovirus ; Cold Temperature ; Cytomegalovirus Infections - blood ; Humans ; Hydrostatic Pressure ; Medical sciences ; PCT = pressure-cycling technology ; PFU(s) = plaque-forming unit(s) ; T-AMY = total amylase ; Temperature ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Virus Activation</subject><ispartof>Transfusion (Philadelphia, Pa.), 2000-02, Vol.40 (2), p.193-200</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5113-8677844b2dd9f6fe1026618f887bc2a606e7d621a69a68997cdb0e6ba0a87eb03</citedby><cites>FETCH-LOGICAL-c5113-8677844b2dd9f6fe1026618f887bc2a606e7d621a69a68997cdb0e6ba0a87eb03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1537-2995.2000.40020193.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1537-2995.2000.40020193.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1318521$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10686003$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bradley, D.W.</creatorcontrib><creatorcontrib>Hess, R.A.</creatorcontrib><creatorcontrib>Tao, F.</creatorcontrib><creatorcontrib>Sciaba-Lentz, L.</creatorcontrib><creatorcontrib>Remaley, A.T.</creatorcontrib><creatorcontrib>Laugharn Jr, J.A.</creatorcontrib><creatorcontrib>Manak, M.</creatorcontrib><title>Pressure cycling technology:a novel approach to virus inactivation in plasma</title><title>Transfusion (Philadelphia, Pa.)</title><addtitle>Transfusion</addtitle><description>BACKGROUND: Hydrostatic‐pressure virus inactivation is a novel approach to the inactivation of pathogens in plasma and blood‐derived components, that retains the therapeutic properties of these products. STUDY DESIGN AND METHODS: A custom‐built apparatus was used to pressurize human plasma samples spiked with lambda phage. Phage titer and plasma protein activities were monitored after pressure treatment. RESULTS: Pressure‐mediated inactivation of lambda phage was found to be an effective means for virus inactivation, particularly when performed at near‐zero (0°C) temperatures, rather than at temperatures above 20°C and below –40°C. The efficiency of inactivation was improved by an increase in applied pressure and repeated cycling from atmospheric to high pressure. In contrast, activities of plasma proteins alkaline phosphatase and total amylase did not vary with temperature and remained within 29 percent and 6 percent, respectively, of starting values after the same pressure treatments. By combining cycling, near‐zero temperatures, and high pressure, phage titers in serum were reduced approximately 6 log after 10 to 20 minutes of treatment. Activities of plasma proteins IgG, IgM, and factor X were at 104 percent, 89 percent, and 80 percent, respectively, of starting values after 20 minutes of the same temperature and pressure treatment. CONCLUSION: High‐pressure procedures may be useful for the inactivation of viruses in blood and other protein‐containing components.</description><subject>ALP = alkaline phosphatase</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Antibodies, Viral - blood</subject><subject>Antibodies, Viral - physiology</subject><subject>Bacteriophage lambda - physiology</subject><subject>Biological and medical sciences</subject><subject>Blood - virology</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>CMV = cytomegalovirus</subject><subject>Cold Temperature</subject><subject>Cytomegalovirus Infections - blood</subject><subject>Humans</subject><subject>Hydrostatic Pressure</subject><subject>Medical sciences</subject><subject>PCT = pressure-cycling technology</subject><subject>PFU(s) = plaque-forming unit(s)</subject><subject>T-AMY = total amylase</subject><subject>Temperature</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Virus Activation</subject><issn>0041-1132</issn><issn>1537-2995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkE1v1DAQhi0EokvhL6BIIG4JYyfxB5xQSwti-VQRR2viOK0Xb7LYybL77_Eq28KVkzXyM--8egh5RqGgUPGXq4LWpciZUnXBAKCoABhQVRa7e2Rx93efLAAqmlNashPyKMZVYpkC-pCcUOCSA5QLsvwSbIxTsJnZG-_662y05qYf_HC9f4VZP2ytz3CzCQOam2wcsq0LU8xcj2Z0Wxzd0Kch23iMa3xMHnToo31yfE_J94u3V2fv8uXny_dnb5a5qVObXHIhZFU1rG1VxztLgXFOZSelaAxDDtyKljOKXCGXSgnTNmB5g4BS2AbKU_Jizk21fk02jnrtorHeY2-HKWoBilFZyQS-nkEThhiD7fQmuDWGvaagDzL1Sh-E6YMwfZCpb2XqXdp-ejwzNWvb_rM720vA8yOA0aDvAvbGxb9cSWXNaMLOZ-y383b_PxX01beL2ynF5HOMi6Pd3cVg-Km5KEWtf3y61PWHcvn1Ywo5L_8AEOOgMg</recordid><startdate>200002</startdate><enddate>200002</enddate><creator>Bradley, D.W.</creator><creator>Hess, R.A.</creator><creator>Tao, F.</creator><creator>Sciaba-Lentz, L.</creator><creator>Remaley, A.T.</creator><creator>Laugharn Jr, J.A.</creator><creator>Manak, M.</creator><general>Blackwell Science Inc</general><general>Blackwell Publishing</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200002</creationdate><title>Pressure cycling technology:a novel approach to virus inactivation in plasma</title><author>Bradley, D.W. ; Hess, R.A. ; Tao, F. ; Sciaba-Lentz, L. ; Remaley, A.T. ; Laugharn Jr, J.A. ; Manak, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5113-8677844b2dd9f6fe1026618f887bc2a606e7d621a69a68997cdb0e6ba0a87eb03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>ALP = alkaline phosphatase</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Antibodies, Viral - blood</topic><topic>Antibodies, Viral - physiology</topic><topic>Bacteriophage lambda - physiology</topic><topic>Biological and medical sciences</topic><topic>Blood - virology</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>CMV = cytomegalovirus</topic><topic>Cold Temperature</topic><topic>Cytomegalovirus Infections - blood</topic><topic>Humans</topic><topic>Hydrostatic Pressure</topic><topic>Medical sciences</topic><topic>PCT = pressure-cycling technology</topic><topic>PFU(s) = plaque-forming unit(s)</topic><topic>T-AMY = total amylase</topic><topic>Temperature</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Virus Activation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bradley, D.W.</creatorcontrib><creatorcontrib>Hess, R.A.</creatorcontrib><creatorcontrib>Tao, F.</creatorcontrib><creatorcontrib>Sciaba-Lentz, L.</creatorcontrib><creatorcontrib>Remaley, A.T.</creatorcontrib><creatorcontrib>Laugharn Jr, J.A.</creatorcontrib><creatorcontrib>Manak, M.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transfusion (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bradley, D.W.</au><au>Hess, R.A.</au><au>Tao, F.</au><au>Sciaba-Lentz, L.</au><au>Remaley, A.T.</au><au>Laugharn Jr, J.A.</au><au>Manak, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pressure cycling technology:a novel approach to virus inactivation in plasma</atitle><jtitle>Transfusion (Philadelphia, Pa.)</jtitle><addtitle>Transfusion</addtitle><date>2000-02</date><risdate>2000</risdate><volume>40</volume><issue>2</issue><spage>193</spage><epage>200</epage><pages>193-200</pages><issn>0041-1132</issn><eissn>1537-2995</eissn><coden>TRANAT</coden><abstract>BACKGROUND: Hydrostatic‐pressure virus inactivation is a novel approach to the inactivation of pathogens in plasma and blood‐derived components, that retains the therapeutic properties of these products. STUDY DESIGN AND METHODS: A custom‐built apparatus was used to pressurize human plasma samples spiked with lambda phage. Phage titer and plasma protein activities were monitored after pressure treatment. RESULTS: Pressure‐mediated inactivation of lambda phage was found to be an effective means for virus inactivation, particularly when performed at near‐zero (0°C) temperatures, rather than at temperatures above 20°C and below –40°C. The efficiency of inactivation was improved by an increase in applied pressure and repeated cycling from atmospheric to high pressure. In contrast, activities of plasma proteins alkaline phosphatase and total amylase did not vary with temperature and remained within 29 percent and 6 percent, respectively, of starting values after the same pressure treatments. By combining cycling, near‐zero temperatures, and high pressure, phage titers in serum were reduced approximately 6 log after 10 to 20 minutes of treatment. Activities of plasma proteins IgG, IgM, and factor X were at 104 percent, 89 percent, and 80 percent, respectively, of starting values after 20 minutes of the same temperature and pressure treatment. CONCLUSION: High‐pressure procedures may be useful for the inactivation of viruses in blood and other protein‐containing components.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Inc</pub><pmid>10686003</pmid><doi>10.1046/j.1537-2995.2000.40020193.x</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0041-1132
ispartof Transfusion (Philadelphia, Pa.), 2000-02, Vol.40 (2), p.193-200
issn 0041-1132
1537-2995
language eng
recordid cdi_proquest_miscellaneous_70921848
source Wiley Online Library - AutoHoldings Journals; MEDLINE
subjects ALP = alkaline phosphatase
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Antibodies, Viral - blood
Antibodies, Viral - physiology
Bacteriophage lambda - physiology
Biological and medical sciences
Blood - virology
Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis
CMV = cytomegalovirus
Cold Temperature
Cytomegalovirus Infections - blood
Humans
Hydrostatic Pressure
Medical sciences
PCT = pressure-cycling technology
PFU(s) = plaque-forming unit(s)
T-AMY = total amylase
Temperature
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Virus Activation
title Pressure cycling technology:a novel approach to virus inactivation in plasma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T17%3A09%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pressure%20cycling%20technology:a%20novel%20approach%20to%20virus%20inactivation%20in%20plasma&rft.jtitle=Transfusion%20(Philadelphia,%20Pa.)&rft.au=Bradley,%20D.W.&rft.date=2000-02&rft.volume=40&rft.issue=2&rft.spage=193&rft.epage=200&rft.pages=193-200&rft.issn=0041-1132&rft.eissn=1537-2995&rft.coden=TRANAT&rft_id=info:doi/10.1046/j.1537-2995.2000.40020193.x&rft_dat=%3Cproquest_cross%3E70921848%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70921848&rft_id=info:pmid/10686003&rfr_iscdi=true